SE0200943D0 - Mutant protein - Google Patents

Mutant protein

Info

Publication number
SE0200943D0
SE0200943D0 SE0200943A SE0200943A SE0200943D0 SE 0200943 D0 SE0200943 D0 SE 0200943D0 SE 0200943 A SE0200943 A SE 0200943A SE 0200943 A SE0200943 A SE 0200943A SE 0200943 D0 SE0200943 D0 SE 0200943D0
Authority
SE
Sweden
Prior art keywords
protein
immunoglobulin
binding
mutated
glutamine
Prior art date
Application number
SE0200943A
Other languages
English (en)
Swedish (sv)
Inventor
Sophia Hober
Original Assignee
Amersham Biosciences Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20287415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0200943(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amersham Biosciences Ab filed Critical Amersham Biosciences Ab
Priority to SE0200943A priority Critical patent/SE0200943D0/xx
Publication of SE0200943D0 publication Critical patent/SE0200943D0/xx
Priority to CN2011104078514A priority patent/CN102516372A/zh
Priority to DK17166519.3T priority patent/DK3249047T3/da
Priority to KR1020127028734A priority patent/KR101307651B1/ko
Priority to CN201110407855.2A priority patent/CN102532284B/zh
Priority to AT03713152T priority patent/ATE431360T1/de
Priority to EP03713152A priority patent/EP1485407B2/fr
Priority to KR1020107026798A priority patent/KR101307700B1/ko
Priority to JP2003578408A priority patent/JP4391830B2/ja
Priority to ES03713152T priority patent/ES2325362T5/es
Priority to KR1020127028735A priority patent/KR101307714B1/ko
Priority to KR1020047015303A priority patent/KR101067181B1/ko
Priority to EP08004374.8A priority patent/EP1972689B1/fr
Priority to DE60327606T priority patent/DE60327606D1/de
Priority to AU2003217119A priority patent/AU2003217119B2/en
Priority to CN2011104134571A priority patent/CN102558317A/zh
Priority to CN2011104078321A priority patent/CN102516371A/zh
Priority to CN038067935A priority patent/CN1642976B/zh
Priority to EP17166519.3A priority patent/EP3249047B1/fr
Priority to CA2479896A priority patent/CA2479896C/fr
Priority to CN2011104134586A priority patent/CN102558318A/zh
Priority to PCT/SE2003/000475 priority patent/WO2003080655A1/fr
Priority to DK08004374.8T priority patent/DK1972689T3/en
Priority to ES08004374.8T priority patent/ES2634145T3/es
Priority to ES17166519T priority patent/ES2783876T3/es
Priority to US10/508,625 priority patent/US7834158B2/en
Priority to US11/363,078 priority patent/US7709209B2/en
Priority to US11/374,532 priority patent/US20060194950A1/en
Priority to US12/568,854 priority patent/US8354510B2/en
Priority to US12/900,958 priority patent/US8198404B2/en
Priority to US13/488,662 priority patent/US9156892B2/en
Priority to US13/740,793 priority patent/US9296791B2/en
Priority to US14/845,817 priority patent/US9534023B2/en
Priority to US15/367,640 priority patent/US10918971B2/en
Priority to US17/153,015 priority patent/US20210162319A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/24—Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00—Aspects relating to sorbent materials
    • B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
    • B01J2220/44—Materials comprising a mixture of organic materials
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00—Aspects relating to sorbent materials
    • B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/52—Sorbents specially adapted for preparative chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0200943A 2002-03-25 2002-03-25 Mutant protein SE0200943D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE0200943A SE0200943D0 (sv) 2002-03-25 2002-03-25 Mutant protein
ES17166519T ES2783876T3 (es) 2002-03-25 2003-03-20 Proteína mutante
US10/508,625 US7834158B2 (en) 2002-03-25 2003-03-20 Mutated immunoglobulin-binding protein
CN2011104134571A CN102558317A (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
EP17166519.3A EP3249047B1 (fr) 2002-03-25 2003-03-20 Protéine mutante
KR1020127028734A KR101307651B1 (ko) 2002-03-25 2003-03-20 돌연변이된 면역글로불린-결합 단백질
CN201110407855.2A CN102532284B (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
AT03713152T ATE431360T1 (de) 2002-03-25 2003-03-20 Mutiertes immunoglobulinbindendes protein
EP03713152A EP1485407B2 (fr) 2002-03-25 2003-03-20 Proteine de liaison a l'immunoglobuline mutee
KR1020107026798A KR101307700B1 (ko) 2002-03-25 2003-03-20 돌연변이된 면역글로불린-결합 단백질
JP2003578408A JP4391830B2 (ja) 2002-03-25 2003-03-20 変異免疫グロブリン結合タンパク質
ES03713152T ES2325362T5 (es) 2002-03-25 2003-03-20 Una proteína de unión a inmunoglobulina mutada
KR1020127028735A KR101307714B1 (ko) 2002-03-25 2003-03-20 돌연변이된 면역글로불린-결합 단백질
KR1020047015303A KR101067181B1 (ko) 2002-03-25 2003-03-20 돌연변이된 면역글로불린-결합 단백질
EP08004374.8A EP1972689B1 (fr) 2002-03-25 2003-03-20 Protéine à liaison d'immunoglobulines mutées
DE60327606T DE60327606D1 (de) 2002-03-25 2003-03-20 Mutiertes immunoglobulinbindendes protein
AU2003217119A AU2003217119B2 (en) 2002-03-25 2003-03-20 A mutated immunoglobulin-binding protein
CN2011104078514A CN102516372A (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
CN2011104078321A CN102516371A (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
CN038067935A CN1642976B (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
DK17166519.3T DK3249047T3 (en) 2002-03-25 2003-03-20 Mutantprotein
CA2479896A CA2479896C (fr) 2002-03-25 2003-03-20 Proteine de liaison a l'immunoglobuline mutee
CN2011104134586A CN102558318A (zh) 2002-03-25 2003-03-20 一种突变的免疫球蛋白-结合蛋白
PCT/SE2003/000475 WO2003080655A1 (fr) 2002-03-25 2003-03-20 Proteine de liaison a l'immunoglobuline mutee
DK08004374.8T DK1972689T3 (en) 2002-03-25 2003-03-20 A mutated immunoglobulin-binding protein
ES08004374.8T ES2634145T3 (es) 2002-03-25 2003-03-20 Proteína de unión a inmunoglobulinas mutada
US11/363,078 US7709209B2 (en) 2002-03-25 2006-02-27 Protein ligands
US11/374,532 US20060194950A1 (en) 2002-03-25 2006-03-13 Mutant protein
US12/568,854 US8354510B2 (en) 2002-03-25 2009-09-29 Mutant protein
US12/900,958 US8198404B2 (en) 2002-03-25 2010-10-08 Mutated immunoglobulin-binding protein
US13/488,662 US9156892B2 (en) 2002-03-25 2012-06-05 Mutated immunoglobulin-binding protein
US13/740,793 US9296791B2 (en) 2002-03-25 2013-01-14 Mutant protein
US14/845,817 US9534023B2 (en) 2002-03-25 2015-09-04 Mutated immunoglobulin-binding protein
US15/367,640 US10918971B2 (en) 2002-03-25 2016-12-02 Mutated immunoglobulin-binding protein
US17/153,015 US20210162319A1 (en) 2002-03-25 2021-01-20 Mutated Immunoglobulin-Binding Polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200943A SE0200943D0 (sv) 2002-03-25 2002-03-25 Mutant protein

Publications (1)

Publication Number Publication Date
SE0200943D0 true SE0200943D0 (sv) 2002-03-25

Family

ID=20287415

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200943A SE0200943D0 (sv) 2002-03-25 2002-03-25 Mutant protein

Country Status (13)

Country Link
US (9) US7834158B2 (fr)
EP (3) EP3249047B1 (fr)
JP (1) JP4391830B2 (fr)
KR (4) KR101307651B1 (fr)
CN (6) CN102532284B (fr)
AT (1) ATE431360T1 (fr)
AU (1) AU2003217119B2 (fr)
CA (1) CA2479896C (fr)
DE (1) DE60327606D1 (fr)
DK (2) DK1972689T3 (fr)
ES (3) ES2783876T3 (fr)
SE (1) SE0200943D0 (fr)
WO (1) WO2003080655A1 (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
SE0301936D0 (sv) * 2003-06-30 2003-06-30 Affibody Ab New polypeptide
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
EP2251425B1 (fr) * 2004-07-06 2016-04-20 Kaneka Corporation Procédé de production d'un assimilé de la protéine A à l'aide de bactérie Brevibacillus
WO2006065208A1 (fr) * 2004-12-14 2006-06-22 Ge Healthcare Bio-Sciences Ab Purification d'immunoglobulines
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
WO2006092338A2 (fr) * 2005-03-01 2006-09-08 Affibody Ab Nouveau polypeptide, utilisations et methodes dans lesquelles celui-ci est utilise
WO2007097361A1 (fr) 2006-02-21 2007-08-30 Protenova Co., Ltd. Ligand presentant une affinite pour les immunoglobulines
WO2008039141A1 (fr) 2006-09-29 2008-04-03 Ge Healthcare Bio-Sciences Ab Ligand de chromatographie comprenant un domaine c issu de la protéine a de staphylococcus aureus pour l'isolement d'anticorps
EP2099932A4 (fr) 2006-12-06 2009-11-18 Repligen Corp Acides nucleiques codant pour la proteine recombinee a
JP5522723B2 (ja) * 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
SG149759A1 (en) 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
GB2452301A (en) * 2007-08-30 2009-03-04 Ge Healthcare Bio Sciences Ab Sterilization Method
KR101104417B1 (ko) * 2008-05-09 2012-01-16 한국생명공학연구원 단백질 ｇ 변형체를 이용한 항체의 특이적 공유결합 커플링방법
EP2281000A2 (fr) * 2008-05-15 2011-02-09 Novo Nordisk A/S Procédé de purification d'anticorps
US9238810B2 (en) 2008-06-05 2016-01-19 Affibody Ab Polypeptide
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
CN102165312B (zh) * 2008-09-25 2015-04-22 Jsr株式会社 亲合层析用填充剂
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
SG195555A1 (en) * 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
EP2389386A4 (fr) * 2009-01-12 2013-11-06 Ge Healthcare Bio Sciences Ab Matrice de chromatographie par affinité
JPWO2010110288A1 (ja) * 2009-03-24 2012-09-27 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
WO2011118699A1 (fr) 2010-03-24 2011-09-29 株式会社カネカ Protéine capable de se lier spécifiquement à une immunoglobuline, et ligand ayant une affinité de liaison pour l'immunoglobuline
KR102006097B1 (ko) 2010-03-31 2019-07-31 제이에스알 가부시끼가이샤 친화성 크로마토그래피용 충전제
US20130052209A1 (en) * 2010-04-23 2013-02-28 Purdue Research Foundation Protein drug formulations and packages
WO2012001142A1 (fr) 2010-07-02 2012-01-05 Novo Nordisk A/S Ligands d'affinité de liaison aux anticorps améliorée
RU2624036C2 (ru) 2010-10-27 2017-06-30 Спибер Текнолоджиз Аб Структуры слитого белка шелка пауков для связывания с органической мишенью
JP2014502272A (ja) * 2010-11-29 2014-01-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス
CN103269762B (zh) * 2010-12-20 2016-01-27 通用电气健康护理生物科学股份公司 亲和色谱基质
JP5974342B2 (ja) * 2010-12-20 2016-08-23 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
US9040661B2 (en) 2010-12-21 2015-05-26 Jsr Corporation Support for affinity chromatography and method for isolating immunoglobulin
WO2012083425A1 (fr) 2010-12-21 2012-06-28 The University Of Western Ontario Nouveaux variants de protéine a résistant aux alcalis et leur utilisation en chromatographie d'affinité
US20130317172A1 (en) * 2010-12-24 2013-11-28 Nomadic Bioscience Co., Ltd. Method for immobilizing temperature responsive protein a
JP6121911B2 (ja) 2011-01-20 2017-04-26 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 光走査システム
WO2012124145A1 (fr) 2011-03-15 2012-09-20 オムロン株式会社 Unité de calcul, unité d'assistance, programme d'assistance, support d'enregistrement contenant un programme d'assistance, et procédé de fonctionnement dans un dispositif d'assistance
US9273151B2 (en) 2011-03-24 2016-03-01 Kaneka Corporation Proteinaceous-substance-binding low-molecular-weight compound
EP2690108B1 (fr) 2011-03-25 2018-07-25 Kaneka Corporation Nouveau polypeptide se liant à l'immunoglobuline
EP4344163A3 (fr) * 2011-06-05 2024-04-24 Apple Inc. Systèmes et procédés d'affichage de notifications reçues de multiples applications
SG186552A1 (en) * 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9657055B2 (en) 2011-11-30 2017-05-23 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
EP2831096B1 (fr) 2012-03-28 2020-04-29 GE Healthcare BioProcess R&D AB Matrice de chromatographie par affinité
US9856308B2 (en) * 2012-05-02 2018-01-02 Spiber Technologies Ab Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands
US9890191B2 (en) 2012-09-03 2018-02-13 Kaneka Corporation Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules
JP6279590B2 (ja) 2012-10-03 2018-02-14 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 酸性条件でアナライトを測定するための方法およびキット
WO2014092636A1 (fr) 2012-12-14 2014-06-19 Ge Healthcare Bio-Sciences Ab Procédé de nettoyage de colonnes de chromatographie à lit garni
CN104059133B (zh) 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 一类突变的具有高耐碱特性的蛋白a及其应用
CN103214563B (zh) * 2013-03-26 2015-09-30 江南大学 一种性能改进的重组金黄色葡萄球菌蛋白a亲和配基及其构建方法
EP3019520B1 (fr) 2013-07-10 2019-12-11 GE Healthcare BioProcess R&D AB Polypeptides de liaison à une immunoglobuline mutante
JP6456831B2 (ja) * 2013-09-04 2019-01-23 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
EP3042954A4 (fr) * 2013-09-06 2017-03-22 Kaneka Corporation Ligand à capacité de dissociation renforcée pour matrice de dissociation par affinité
JPWO2015041218A1 (ja) 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
CN103540588B (zh) * 2013-10-08 2016-06-08 杨波 一种基因工程改造的免疫球蛋白-亲和蛋白
EP3059251B1 (fr) 2013-10-15 2019-04-03 Kaneka Corporation Procédé de fabrication de billes poreuses en cellulose
EP3059252B1 (fr) 2013-10-15 2018-12-05 Kaneka Corporation Procédé de production de billes de cellulose poreuses et agent absorbant en decoulant
EP3059320A4 (fr) 2013-10-15 2017-06-21 Kaneka Corporation Procédé de production de billes poreuses de cellulose et absorbant les utilisant
CN104945488B (zh) * 2014-03-27 2020-02-18 迈格生物医药（上海）有限公司 一种具有免疫球蛋白结合能力的多肽
CN105481954B (zh) * 2014-09-16 2021-03-26 亿一生物制药(北京)有限公司 一种重组蛋白a及其应用
JP6369807B2 (ja) * 2014-10-21 2018-08-08 株式会社プロテイン・エクスプレス プロテインｌ変異体
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7204086B2 (ja) 2014-12-17 2023-01-16 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 改変κ軽鎖結合ポリペプチド
WO2016121701A1 (fr) 2015-01-26 2016-08-04 株式会社カネカ Matrice pour séparation par affinité destinée à la purification de protéines contenant la région variable de la chaîne kappa des immunoglobulines
CN108064286A (zh) 2015-01-26 2018-05-22 株式会社钟化 突变型免疫球蛋白κ链可变区结合性肽
CN107428807A (zh) 2015-02-05 2017-12-01 三菱化学株式会社 对免疫球蛋白具有亲和性的蛋白质和使用它的亲和分离剂、液相色谱柱
JP6705806B2 (ja) * 2015-03-26 2020-06-03 Jsr株式会社 イムノグロブリン結合タンパク質およびそれを用いたアフィニティー担体
CN106188251B (zh) * 2015-05-06 2020-07-31 上海迈泰君奥生物技术有限公司 一种免疫球蛋白结合蛋白突变体及其用途
WO2017014257A1 (fr) * 2015-07-22 2017-01-26 株式会社カネカ PROTÉINE DE LIAISON À UN ANTICORPS À CAPACITÉ DE LIAISON À UN ANTICORPS DIMINUANT DANS UNE RÉGION DE pH ACIDE
WO2017014261A1 (fr) * 2015-07-22 2017-01-26 株式会社カネカ Procédé de purification de protéine type anticorps
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
KR101993845B1 (ko) * 2016-02-18 2019-06-28 (주)에이피테크놀로지 알칼리 저항성이 증대된 항체 친화성 리간드
WO2017191748A1 (fr) * 2016-05-02 2017-11-09 株式会社カネカ Peptide modifié de liaison à région variable de chaîne κ d'immunoglobuline
WO2017195638A1 (fr) 2016-05-09 2017-11-16 株式会社カネカ Procédé de purification d'un anticorps ou d'un fragment d'anticorps comportant une région variable de chaîne κ
WO2017194593A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de nettoyage et/ou de désinfection d'une matrice de séparation
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194592A1 (fr) * 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de conservation d'une matrice de séparation
KR101857953B1 (ko) * 2016-07-06 2018-05-16 아미코젠주식회사 알칼리 내성이 증가된 변이 면역글로불린 결합 단백질
CN106117324A (zh) * 2016-07-29 2016-11-16 湖北爱晟生物科技有限公司 重组蛋白a及其编码基因和应用
CN109963864B (zh) * 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
WO2018048941A2 (fr) * 2016-09-08 2018-03-15 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de liants de produits d'anticorps monoclonaux à affinité élevée pour augmenter la durée d'action de produits d'anticorps monoclonaux thérapeutiques dans un tissu biologique
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106543274B (zh) * 2016-10-18 2020-10-27 天津大学 一种对抗体具有特异性结合作用的a蛋白结构域z的衍生物及其应用
EP3551646A1 (fr) 2016-12-12 2019-10-16 HurraH S.à r.l. Compositions et procédés d'augmentation des capacités de liaison à l'immunoglobuline de polypeptides et d'oligopeptides se liant à l'immunoglobuline
GB201703116D0 (en) 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
GB201708277D0 (en) 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
EP3521304B9 (fr) 2018-02-01 2023-10-04 Repligen Corporation Protéines de liaison fc avec la cystéine dans la région hélicoïdale c-terminale
CN111315887B (zh) * 2017-11-09 2024-02-06 东曹株式会社 免疫球蛋白结合性蛋白质
CN109721645A (zh) * 2017-12-29 2019-05-07 兆生生物科技南京有限公司 一种基因突变的蛋白a及其应用
GB201800448D0 (en) 2018-01-11 2018-02-28 Puridify Ltd Chromatography media and methods for producing them
WO2019183334A1 (fr) 2018-03-21 2019-09-26 Waters Technologies Corporation Préparation d'échantillon à base d'affinité élevée sans anticorps, sorbants, dispositifs et méthodes
EP3842536A4 (fr) * 2018-08-24 2023-01-18 JSR Corporation Protéine de liaison à l'immunoglobuline et support d'affinité l'utilisant
JP7117741B2 (ja) * 2018-10-10 2022-08-15 国立大学法人 鹿児島大学 ＩｇＧ結合性ペプチドを含む固相担体及びＩｇＧの分離方法
CN113348176A (zh) * 2019-02-01 2021-09-03 纳维格蛋白质有限公司 用于亲和纯化的免疫球蛋白结合蛋白
WO2020196938A1 (fr) * 2019-03-25 2020-10-01 아미코젠주식회사 Résine de purification d'anticorps ayant un excellent potentiel d'élimination d'impuretés
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
WO2020214792A1 (fr) * 2019-04-17 2020-10-22 Bristol-Myers Squibb Company Procédés de régénération de résines de chromatographie
WO2020221781A1 (fr) 2019-04-29 2020-11-05 Cytiva Bioprocess R&D Ab Procédé de séparation d'anticorps ou de fragments d'anticorps dépourvus d'une région fc capable de se lier à la protéine a
CN112210013A (zh) * 2019-07-03 2021-01-12 拜奥普罗塞亚科技有限责任公司 碱耐受性亲和色谱配体
IL292133A (en) 2019-10-18 2022-06-01 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN111057153B (zh) * 2019-12-06 2021-09-07 广州康盛生物科技股份有限公司 一种免疫球蛋白结合蛋白及其制备方法和应用
CN112461943A (zh) * 2020-10-12 2021-03-09 河南省奶牛生产性能测定有限公司 一种牛乳中免疫球蛋白igG高效液相色谱检测方法
WO2022081779A1 (fr) 2020-10-13 2022-04-21 Avitide LLC Banques de ligands d'affinité de protéines à faisceau à trois hélices et utilisations associées
GB202018588D0 (en) 2020-11-26 2021-01-13 Cytiva Bioprocess R & D Ab Separation matrix
WO2022136440A1 (fr) 2020-12-21 2022-06-30 Syngenta Crop Protection Ag Polypeptides d'hexatoxine pesticides et procédés d'utilisation associés
EP4294542A1 (fr) 2021-02-19 2023-12-27 Avitide LLC Agents d'affinité aav2
KR20230174243A (ko) 2021-04-21 2023-12-27 니혼 메디피직스 가부시키가이샤 β선을 방출하는 핵종으로 표지된 인간화 항체
US20240207461A1 (en) 2021-04-21 2024-06-27 Nihon Medi-Physics Co., Ltd. Radioactive antitumor agent
GB2609185A (en) 2021-05-24 2023-02-01 Astrea Uk Services Ltd Scaffold for isolation of a biomolecule
GB202109246D0 (en) 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
CN114315996B (zh) * 2021-12-31 2023-01-17 博格隆(浙江)生物技术有限公司 一种重组ProteinA蛋白及亲和层析介质的制备方法
CN114409748A (zh) * 2022-01-28 2022-04-29 博格隆(浙江)生物技术有限公司 蛋白a的b结构域和z结构域突变体及其应用
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
CN114605508B (zh) * 2022-05-11 2022-07-29 北京达成生物科技有限公司 能够结合于抗体分子Fc区域的抗体结合蛋白及其应用
CN117700501A (zh) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 免疫球蛋白结合蛋白及其应用
KR20250093372A (ko) 2022-10-26 2025-06-24 니혼 메디피직스 가부시키가이샤 방사성 의약 조성물
CN117024529B (zh) * 2023-07-17 2024-01-26 北京达成生物科技有限公司 抗体结合蛋白及其应用
EP4541814A1 (fr) 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Polypeptides stabilisés
EP4541444A1 (fr) 2023-10-20 2025-04-23 Cytiva BioProcess R&D AB Protéine de fusion pour capture d'affinité
EP4563159A1 (fr) 2023-12-01 2025-06-04 Forschungszentrum Borstel, Leibniz Lungenzentrum Vaccination muqueuse par l'intermédiaire d'une boucle de rétroaction iga
EP4660200A1 (fr) 2024-06-03 2025-12-10 MU Bioteknik Aktiebolag Polynucleotide stabilise
WO2026057420A1 (fr) 2024-09-10 2026-03-19 Cytiva Bioprocess R&D Ab Ligand d'affinité pour la purification d'anticorps d'isotype iga

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
EP0550771B1 (fr) 1991-07-25 1999-09-29 Oriental Yeast Co., Ltd. Protein artificielle de liaison avec les immunoglobulines
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US7709209B2 (en) * 2002-03-25 2010-05-04 Ge Healthcare Bio-Sciences Ab Protein ligands
CA2531238C (fr) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
WO2006092338A2 (fr) * 2005-03-01 2006-09-08 Affibody Ab Nouveau polypeptide, utilisations et methodes dans lesquelles celui-ci est utilise
EP2389386A4 (fr) * 2009-01-12 2013-11-06 Ge Healthcare Bio Sciences Ab Matrice de chromatographie par affinité
WO2012083425A1 (fr) * 2010-12-21 2012-06-28 The University Of Western Ontario Nouveaux variants de protéine a résistant aux alcalis et leur utilisation en chromatographie d'affinité
EP3019520B1 (fr) * 2013-07-10 2019-12-11 GE Healthcare BioProcess R&D AB Polypeptides de liaison à une immunoglobuline mutante
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) * 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) * 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) * 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix

Also Published As

Publication number Publication date
CA2479896A1 (fr) 2003-10-02
US20130184438A1 (en) 2013-07-18
ES2325362T3 (es) 2009-09-02
CN1642976A (zh) 2005-07-20
EP1485407A1 (fr) 2004-12-15
KR20120126129A (ko) 2012-11-20
KR101307651B1 (ko) 2013-09-12
CN102558318A (zh) 2012-07-11
EP1972689A3 (fr) 2008-11-19
EP1485407B1 (fr) 2009-05-13
KR20110004456A (ko) 2011-01-13
US20210162319A1 (en) 2021-06-03
KR101307700B1 (ko) 2013-09-11
JP4391830B2 (ja) 2009-12-24
US20160152668A1 (en) 2016-06-02
EP3249047A3 (fr) 2018-02-28
US20050143566A1 (en) 2005-06-30
US20120238724A1 (en) 2012-09-20
AU2003217119A1 (en) 2003-10-08
WO2003080655A1 (fr) 2003-10-02
JP2005538693A (ja) 2005-12-22
ATE431360T1 (de) 2009-05-15
US20170080358A1 (en) 2017-03-23
EP3249047A2 (fr) 2017-11-29
CA2479896C (fr) 2015-11-17
EP1972689A2 (fr) 2008-09-24
CN102516372A (zh) 2012-06-27
KR101307714B1 (ko) 2013-09-11
DK1972689T3 (en) 2017-08-14
US20060194950A1 (en) 2006-08-31
CN102516371A (zh) 2012-06-27
US8198404B2 (en) 2012-06-12
US9296791B2 (en) 2016-03-29
US8354510B2 (en) 2013-01-15
DE60327606D1 (de) 2009-06-25
DK3249047T3 (en) 2020-03-30
ES2325362T5 (es) 2013-02-20
EP1972689B1 (fr) 2017-06-07
US20100022760A1 (en) 2010-01-28
US10918971B2 (en) 2021-02-16
ES2634145T3 (es) 2017-09-26
EP3249047B1 (fr) 2020-02-19
CN102532284A (zh) 2012-07-04
CN1642976B (zh) 2012-02-22
CN102532284B (zh) 2014-04-16
US7834158B2 (en) 2010-11-16
KR20040099368A (ko) 2004-11-26
ES2783876T3 (es) 2020-09-18
KR20120125674A (ko) 2012-11-16
AU2003217119B2 (en) 2010-02-18
US20110112276A1 (en) 2011-05-12
CN102558317A (zh) 2012-07-11
US9156892B2 (en) 2015-10-13
EP1485407B2 (fr) 2012-09-26
KR101067181B1 (ko) 2011-09-22
US9534023B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
SE0200943D0 (sv) Mutant protein
Linhult et al. Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach
DK1562972T3 (da) Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
Rustandi et al. Applications of CE SDS gel in development of biopharmaceutical antibody‐based products
BRPI0409269A (pt) anticorpo modificado da classe igg e método de produção do mesmo
EP2157099B1 (fr) Nouvelles protéines se liant à des immunoglobulines dont la spécificité est améliorée
WO2004003220A3 (fr) Methodes et compositions permettant d'analyser des echantillons affaiblis, au moyen de panels de polymorphismes nucleotidiques uniques
WO2004074310A8 (fr) Diagnostics de mycobactéries
ATE388230T1 (de) Neisseria meningitidis antigene und zusammenstellungen
McCue et al. Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein
WO2004067779A3 (fr) Polymorphismes genetiques associes a l'arthrite rhumatoide, procedes de detection et utilisations associees
DK1240337T3 (da) Fremgangsmåder og præparater til forlængelse af elimeneringshalveringstider af bioaktive forbindelser
WO2003092581A3 (fr) Composes de capture, recueils de ceux-ci et procedes d'analyse du proteome et compositions complexes
ATE480573T1 (de) Pfropfcopolymere, deren herstellung und verwendung bei der kapillarelektrophorese
Yoshida et al. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.
DK1404428T3 (da) Fremgangsmåder til oprensning af stærkt anioniske proteiner
WO2004106367A3 (fr) Antigenes d'enterococcus
ATE469162T1 (de) Verfahren und zusammensetzungen zur identifizierung und charakterisierung von hepatitis c
DK1105508T3 (da) Fremgangsmåde til oprensning af biomolekyle- eller proteinkomplekser
JPWO2006001300A1 (ja) 高耐久性液体クロマトグラフィー用充填剤
WO2002095067A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifnα-14
WO2003014398A3 (fr) Procedes et compositions de detection de mutations par chromatographie liquide
Troxler et al. Detection of a novel variant human hemoglobin by electrospray ionization mass spectrometry
WO2005100386A3 (fr) Récepteur de canine sensible au froid et au menthol 1
WO2005000883A8 (fr) Variantes de la proteine a des staphylocoques et procedes s'y rapportant